Association of biological characteristics of hepatitis B virus with the progression of liver fibrosis

Chang XiuJuan; Li YinYin; Yang Bin; Ceng Zhen; Huang JiaGan; Yang YongPing

doi:10.3969/j.issn.1001-5256.2019.08.041

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1834-1837

PDF( 1929 KB)

Association of biological characteristics of hepatitis B virus with the progression of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.08.041

Chinese PLA Medical School

Research funding:

Received Date: 2019-03-19
Published Date: 2019-08-20

Abstract

Abstract

Hepatitis B virus (HBV) causes liver injury by stimulating host immune response and may lead to liver fibrosis, liver cirrhosis, and liver cancer. Progression of liver fibrosis is a key factor in liver disease-related death. This article summarizes the association of HBV genotype, HBV gene mutation in basic core promoter region/pre-C region, pre-S region, and X region, HBV gene splicing, HBV RNA, HBcAg, and HBsAg with the progression of liver fibrosis. It is pointed out that the above biological characteristics of HBV are closely associated with the progression of liver fibrosis.
- hepatitis B virus,
- liver cirrhosis,
- genes,
- genotype

FullText(HTML)

References(37)

References

[1] TANG LSY, COVERT E, WILSON E, et al. Chronic hepatitis B infection:A review[J]. JAMA, 2018, 319 (17) :1802-1813.

[2] TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63 (1) :261-283.

[3] TIAN Q, JIA J. Hepatitis B virus genotypes:Epidemiological and clinical relevance in Asia[J]. Hepatol Int, 2016, 10 (6) :854-860.

[4] SUNBUL M. Hepatitis B virus genotypes:Global distribution and clinical importance[J]. World J Gastroenterol, 2014, 20 (18) :5427-5434.

[5] BAYLISS J, YUEN L, ROSENBERG G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBe Ag-positive chronic hepatitis B[J]. Gut, 2017, 66 (11) :2013-2023.

[6] SUN YH, LEI XY, SAI YP, et al. Relationship between genotypes and clinical manifestation, pathology, and cccDNA in Chinese children with hepatitis B virus-associated glomerulonephritis[J]. World J Pediatr, 2016, 12 (3) :347-352.

[7] LI X, QIN Y, LIU Y, et al. Pre S deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection[J]. J Clin Virol, 2016, 82:27-32.

[8] YANG HC, KAO JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes:Molecular mechanisms and clinical significance[J]. Emerg Microbes Infect, 2014, 3 (9) :e64.

[9] CHOTIYAPUTTA W, LOK AS. Hepatitis B virus variants[J].Nat Rev Gastroenterol Hepatol, 2009, 6 (8) :453-462.

[10] LINDH M, HORAL P, DHILLON AP, et al. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage[J]. Hepatology, 1996, 24 (3) :494-501.

[11] CHACHSGF, GOMES-GOUVEA MS, MALTA FM, et al.Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases[J]. Mem Inst Oswaldo Cruz, 2017, 112 (9) :626-631.

[11] CHU CM, LIN CC, CHEN YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection[J]. Br J Cancer, 2012, 107 (12) :2010-2015.

[12] TONG S, KIM KH, CHANTE C, et al. Hepatitis B virus e antigen variants[J]. Int J Med Sci, 2005, 2 (1) :2-7.

[13] LAPALUS M, LAOUENAN C, CARDOSO AC, et al. Precore/Core promoter variants to predict significant fibrosis in both HBe Ag positive and negative chronic hepatitis B[J]. Liver Int, 2015, 35 (9) :2082-2089.

[14] TSENG TC, LIU CJ, YANG HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers[J]. Gut, 2015, 64 (2) :292-302.

[15] DUCANCELLE A, PIVERT A, BERTRAIS S, et al. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity[J]. J Gastroenterol Hepatol, 2016, 31 (10) :1750-1756.

[16] KITAB B, ESSAID EL FEYDI A, AFIFI R, et al. Variability in the precore and core promoter regions of HBV strains in Morocco:Characterization and impact on liver disease progression[J].PLo S One, 2012, 7 (8) :e42891.

[17] CASTELAIN S, DESCAMPS V, BROCHOT E, et al. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBe Ag-negative chronically infected patients[J]. Arch Virol, 2017, 162 (7) :1913-1920.

[18] TENG YC, NEO JC, WU JC, et al. Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice[J]. J Pathol, 2017, 241 (4) :463-474.

[19] DONG Q, CHAN HL, LIU Z, et al. A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities[J]. Biochem Biophys Res Commun, 2008, 374 (4) :773-776.

[20] GONG J, TU W, HAN J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx[J]. Sci Rep, 2016, 6:37717.

[21] KANG HJ, CHUNG DH, SUNG CO, et al. SHP2 is induced by the HBx-NF-kappaB pathway and contributes to fibrosis during human early hepatocellular carcinoma development[J]. Oncotarget, 2017, 8 (16) :27263-27276.

[22] REDELSPERGER F, LEKBABY B, MANDOURI Y, et al. Production of hepatitis B defective particles is dependent on liver status[J]. Virology, 2012, 431 (1-2) :21-28.

[23] DURIEZ M, MANDOURI Y, LEKBABY B, et al. Alternative splicing of hepatitis B virus:A novel virus/host interaction altering liver immunity[J]. J Hepatol, 2017, 67 (4) :687-699.

[24] PERRI S, GANEM D. A host factor that binds near the termini of hepatitis B virus pregenomic RNA[J]. J Virol, 1996, 70 (10) :6803-6809.

[25] WANG J, YU Y, LI G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017.[Epub ahead of print]

[26] KIMURA T, ROKUHARA A, SAKAMOTO Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J]. J Clin Microbiol, 2002, 40 (2) :439-445.

[27] KIMURA T, OHNO N, TERADA N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain[J]. J Biol Chem, 2005, 280 (23) :21713-21719.

[28] SETO WK, TANAKA Y, WONG DK, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels:Re-evaluation of HBsAg seroclearance[J]. Liver Int, 2016, 36 (5) :642-650.

[29] TADA T, KUMADA T, TOYODA H, et al. Hepatitis B virus corerelated antigen levels predict progression to liver cirrhosis in hepatitis B carriers[J]. J Gastroenterol Hepatol, 2017, 33 (4) :918-925.

[30] SUN C, CHANG XJ, LI XD, et al. Value of hepatitis B virus core-related antigen in predicting the natural course of chronic hepatitis B and liver fibrosis regression[J]. J Clin Hepatol, 2019, 35 (2) :328-333. (in Chinese) 孙超, 常秀娟, 李晓东, 等. HBcrAg在慢性乙型肝炎自然进程及预判肝纤维化逆转中的应用价值[J].临床肝胆病杂志, 2019, 35 (2) :328-333.

[31] WANG S, CHEN Z, HU C, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation[J]. J Immunol, 2013, 190 (10) :5142-5151.

[32] SEEGER C, MASON WS. Hepatitis B virus biology[J]. Microbiol Mol Biol Rev, 2000, 64 (1) :51-68.

[33] LARSSON SB, MALMSTRM S, HANNOUN C, et al. Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection[J]. Virol J, 2015, 12:213.

[34] MASON WS, GILL U S, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151 (5) :986-998.

[35] GOYAL SK, JAIN AK, DIXIT VK, et al. HBsAg level as predictor of liver fibrosis in HBe Ag positive patients with chronic hepatitis B virus infection[J]. J Clin Exp Hepatol, 2015, 5 (3) :213-220.

[36] MARTINOT-PEIGNOUX M, LAPALUS M, ASSELAH T, et al.HBsAg quantification:Useful for monitoring natural history and treatment outcome[J]. Liver Int, 2014, 34 (Suppl 1) :97-107.

Relative Articles

[1]	Zhang ChunYu, Liu ZuoJin. Surgical treatment of cirrhotic portal hypertension: Current status and research advances[J]. Journal of Clinical Hepatology, 2020, 36(2): 417-420. doi: 10.3969/j.issn.1001-5256.2020.02.040
[2]	Yao Xin, Zhou Hao, Tang ShanHong, Huang Shan, Chen XueLing, Qin JianPing. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2020, 36(9): 1970-1974. doi: 10.3969/j.issn.1001-5256.2020.09.012
[3]	Mu XueChun, Wang Yu, Ma Hong. Noninvasive assessment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(12): 2796-2799. doi: 10.3969/j.issn.1001-5256.2019.12.033
[4]	Xiao Peng, Zhang YaNan, Ba TaoTao, Ding MengMeng, Gao YanHang. Application of serological markers in noninvasive assessment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(9): 2075-2078. doi: 10.3969/j.issn.1001-5256.2019.09.042
[5]	Xu Hui, Zhang Feng, Zhang Ming, Zhu GeYuZheng. Effect of propranolol on hemodynamics and its clinical significance in patients with portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(4): 801-807. doi: 10.3969/j.issn.1001-5256.2019.04.019
[6]	He Bo, Zhang ChunQing. Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(2): 399-401. doi: 10.3969/j.issn.1001-5256.2019.02.036
[7]	Wang Lin, Xu JiPing, Liu Jing, Ma XianChun, Sun WenBing. Anesthetic management strategies for patients with cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 188-191. doi: 10.3969/j.issn.1001-5256.2018.01.041
[8]	Niu XiaoWei, Liu TongTing, Wei Zhi. Advances in the effect of carvedilol in prevention and treatment of esophageal variceal bleeding in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 184-187. doi: 10.3969/j.issn.1001-5256.2018.01.040
[9]	Han Dan, Qi XingShun, Yu Yang, Zhu Qiang, Guo XiaoZhong. An excerpt of portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis and management - 2016 practice guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2017, 33(3): 422-427. doi: 10.3969/j.issn.1001-5256.2017.03.004
[10]	Nie Wei, Lin Wei, Liang Shan, Fan ZuoPeng, Chou LiXia, Liu YiRong, Ma LiXia, Wei XinHuan, Hu ZhongJie, Zhang Jing. Clinical features of cirrhotic patients with different degrees of portal vein thrombosis and their clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(3): 472-475. doi: 10.3969/j.issn.1001-5256.2017.03.015
[12]	Ding Qian, Li Zhen, Liu Bin, Ling LiPing, Zhang ChunQing. Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action[J]. Journal of Clinical Hepatology, 2017, 33(3): 485-491. doi: 10.3969/j.issn.1001-5256.2017.03.018
[13]	Zhai YaNan, Li Lei, Yin Liang, Guo QiHong, Lei JunQiang, Guo ShunLin, Zhang ChunYu, Wang HaiJun, Wen XiaoXiao. Role of dual-source CT low-dose whole liver perfusion imaging in evaluating liver blood perfusion after transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(10): 1894-1899. doi: 10.3969/j.issn.1001-5256.2016.10.014
[14]	Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
[15]	Lu XiaoMin, Wang ZhenNing, Yang Jun. Significance of molecular markers of prethrombotic state in monitoring portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 404-406. doi: 10.3969/j.issn.1001-5256.2015.03.022
[16]	Yang ChunJiao, Qi XingShun, Guo XiaoZhong. Research advances in role of carvedilol in management of cirrhotic portal hypertension: a review of clinical trials[J]. Journal of Clinical Hepatology, 2015, 31(3): 469-471. doi: 10.3969/j.issn.1001-5256.2015.03.038
[17]	Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
[18]	Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	鞠迪，李汨，韩曼，房冰莹，闫曙光，安荣，李京涛. 益脾养肝方对肝癌前病变大鼠肝星状细胞活化的影响. 陕西中医药大学学报. 2024(02): 83-88 .
2.	黄玉，苟雪源，关茜，焦俊喆，闫曙光，常占杰，闫瑞娟，李京涛. 基于M1型巨噬细胞极化-慢性炎症-肝细胞恶变探究益脾养肝方治疗肝癌前病变作用机制. 中国中医药信息杂志. 2024(10): 81-88 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1101) PDF downloads(225)

Association of biological characteristics of hepatitis B virus with the progression of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.08.041